Extended-release oral capsule of carbidopa-levodopa in parkinson disease

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa-levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action and fewer doses per day, similar clinical improvement when compared to other levodopa formulations, and with a theoretically lower risk of developing motor fluctuations. Several studies, including three randomized control trials provide evidence for the efficacy, safety and tolerability of extended release carbidopa- levodopa in patients with both early and advanced Parkinson’s disease are reviewed here. Also provided is guidance for dosing of and conversion to extended release carbidopa-levodopa as well as a discussion of its place in the clinical practice.

Original languageEnglish (US)
JournalTherapeutic Advances in Neurological Disorders
StatePublished - Jan 1 2018


  • Extended release carbidopa-levodopa
  • Parkinson’s disease
  • Rytary

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Extended-release oral capsule of carbidopa-levodopa in parkinson disease'. Together they form a unique fingerprint.

Cite this